Trends in opioid analgesics consumption, Israel, 2000–2008

Ponizovsky, Alexander M.; Marom, Eli; Zeldin, Alexander

doi:10.1007/s00228-010-0932-0

Cited by 29 publications

(33 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fentanyl and morphine sales (Figure 2) were comparable to that of other European Countries,22 and almost superimposable to data observed in Nordic Countries7 and Israel 23. The sales of fentanyl increased from 0.011 to 0.468 DDDs/day/1000 inhabitants between 2000 and 2010, whereas morphine sales decreased from 0.113 to 0.084 DDDs/day/1000 inhabitants in the same period (Figure 2).…”

Section: The Effect Of Technological Innovationsupporting

confidence: 77%

Do laws impact opioids consumption? A breakpoint analysis based on Italian sales data

Musazzi¹,

Rocco²,

Brunelli³

et al. 2018

JPR

View full text Add to dashboard Cite

PurposeIn Italy, where the adoption of opioid analgesics in pain management has been historically poor, an increase in opioids consumption occurred between 2000 and 2015. The aim of this study is to assess, through specific time series analyses for trend changes, the impact of different intervening factors – such as the availability of new drugs, the observance of clinical guidelines, changes in prescription regulations, and in reimbursement policies – on opioids sales to community pharmacies in Italy, focusing on the time period 2000–2010.Materials and methodsFive opioids were considered: codeine, tramadol, buprenorphine, morphine, and fentanyl. The analysis is based on sales data collected at wholesale distributors. For each one of the five drugs, time series of the number of Defined Daily Doses per thousand inhabitants per day in the period 2000–2010 were analyzed, and an estimation of breakpoints was performed using segmented linear regression.ResultsDrug sales underwent a sharp increase in 2000–2010, although on different scales. Segmented regression analysis highlighted different potential breakpoints, corresponding to either a significant change in value and/or in slope. Sales of the five opioids were affected by at least one relevant event, often due to a synergy of regulatory, marketing, and technological factors. The effect of reimbursement changes has proved important.ConclusionBetween 2000 and 2010, regulatory, technological, and reimbursement changes significantly influenced opioid sales to community pharmacies in Italy. The sales of relatively new drug products seem to be less influenced by changes in reimbursement and regulatory policies than that of more established products, suggesting that physicians are more comfortable with “old” drugs, since their clinical use is supported by established clinical guidelines and protocols.

show abstract

Section: The Effect Of Technological Innovationsupporting

confidence: 77%

Do laws impact opioids consumption? A breakpoint analysis based on Italian sales data

Musazzi¹,

Rocco²,

Brunelli³

et al. 2018

JPR

View full text Add to dashboard Cite

show abstract

“…The decreasing trend in pethidine use noted in Taiwan is consistent with previous reports from other nations (11,12),. Joranson et al (23) retrospectively surveyed the U.S. medical record database, which revealed a 35% decrease (5.2 to 3.4 million grams) in the medical use of pethidine from 1990 to 1996.…”

Section: Discussionsupporting

confidence: 91%

“…Gilson et al (22) also used the same database to demonstrate that there was a further decline in medical use of pethidine by over 6% (5.8 to 5.4 million grams) from 1997 through 2002. Additionally, in Israel from 2000 to 2008, pethidine consumption fell by 65%, from 0.07 to 0.02 DDD/1,000 inhabitants/day (12). However, two population-based surveys found that pethidine consumption was less than 0.01 DDD/1,000 inhabitants/day and remained constant in both Spain between 1992 and 2006 (11) and in the Slovak Republic between 1998 and 2002 (24).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, multifaceted education, combining a pethidine formulary restriction and a computerized provider order entry regulation initiative, has also minimized pethidine prescriptions (25-27). Furthermore, restricting the use of pethidine to patients who are allergic to or unable to tolerate all other opioids has been advocated in Taiwan as well as in many other countries worldwide (3,12). …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Trends and characteristics of pethidine use in Taiwan: a six-year-long survey

Pan¹,

Li²,

Lin³

et al. 2012

Clinics

View full text Add to dashboard Cite

OBJECTIVES:To investigate the trends and characteristics of pethidine prescriptions and users in Taiwan from 2002 to 2007.METHOD:All pethidine users (n = 3,301,136) in Taiwan from 2002 to 2007 were linked to National Health Insurance claims to identify pethidine prescriptions. We examined the trends in pethidine user prevalence and the proportion of pethidine prescriptions according to health care characteristics. A logistic regression model was used to compare patient demographics and health care characteristics associated with pethidine prescriptions between 2002 and 2007.RESULTS:Despite the decline in the number of pethidine users and prescriptions over the six-year period, more than half a million people were prescribed pethidine annually. In fact, an increasing proportion of pethidine prescriptions were observed in clinics, outpatient settings, and patients who had both operations and cancer diagnoses. Pethidine prescriptions were mostly associated with a non-operation status without a cancer diagnosis (>60%). However, approximately 10% of the total pethidine prescriptions were found in patients with a cancer diagnosis but no operation. Compared to those in 2002, pethidine prescriptions in 2007 were more likely to be found in people 80 years or older, rural residents, patients from clinics, outpatient settings and operation patients with cancer diagnoses.CONCLUSIONS:A population-based survey in Taiwan demonstrated decreasing consumption of pethidine from 2002 to 2007; however, an increased proportion of prescriptions in certain health care settings was observed. In addition, 10% of the pethidine prescriptions were for cancer patients without operations. These cases need further evaluation for the determination of appropriate pethidine use.

show abstract

“…From 2002 to 2006, the prescribing rate (DDDs) of oxycodone increased four times in Norway, while the rate doubled in Sweden and Finland [25]. From 2004 to 2006, the prescribing rate (DDDs) of oxycodone increased by 239% in Iceland [25], 94% in Italy [26] and 50% in Israel [27]. No studies have analysed why some physicians seem to have a preference for oxycodone, but some studies indicate that strategic pharmaceutical marketing and physicians' concern about addiction and abuse may have had an impact [28][29][30].…”

Section: Introductionmentioning

confidence: 99%

General Practitioners' and Hospital Physicians' Preference for Morphine or Oxycodone as First‐Time Choice for a Strong Opioid: A National Register–Based Study

Poulsen

Andersen

Moreno³

et al. 2012

Basic Clin Pharma Tox

View full text Add to dashboard Cite

The aim of this study was to characterize first-time oxycodone and morphine prescriptions in outpatients by type of prescriber and naivety in regard to strong opioids. All prescriptions for morphine and oxycodone in Denmark reported to the National Register of Medicinal Product Statistics in 2010 were analysed. If a patient had not had a prescription filled for the same drug within the last 2 years, the prescription was defined as a first-time prescription. Patients who had not received a prescription for strong opioids for 6 months prior to the date of redemption were classified as strong opioid naive. The odds ratio (OR) was calculated to investigate whether general practitioners (GPs) and hospital physicians had similar preferences for oxycodone over morphine for strong opioid-naive patients. We included 69,110 first-time prescriptions, of which 59,316 (86%) were for strong opioid-naive patients. Opioid-naive patients received 79% of the first-time prescriptions for morphine and 91% of the prescriptions for oxycodone. Hospital physicians had a greater preference for oxycodone over morphine than GPs (OR 1.34, 95% CI 1.29-1.39). However, GPs were responsible for approximately 61% of all first-time prescriptions for both oxycodone and morphine for strong opioid-naive patients. In conclusion, oxycodone is to a great extent prescribed as the first-choice strong opioid, and both GPs and hospital physicians seem to contribute to this prescribing pattern of strong opioids to outpatients.

show abstract

Trends in opioid analgesics consumption, Israel, 2000–2008

Cited by 29 publications

References 15 publications

Do laws impact opioids consumption? A breakpoint analysis based on Italian sales data

Do laws impact opioids consumption? A breakpoint analysis based on Italian sales data

Trends and characteristics of pethidine use in Taiwan: a six-year-long survey

General Practitioners' and Hospital Physicians' Preference for Morphine or Oxycodone as First‐Time Choice for a Strong Opioid: A National Register–Based Study

Contact Info

Product

Resources

About